BUY Biocon Ltd — Sachin Janardan Sarvade, IDBI Capital Markets and Securities
bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: NA (inferred Swing (≤2wk))13 Jul 2026via NDTV Profit (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
4 advisors have active short-term BUY calls on this stock, with 3 issued in the last 14 days
Advisor consensus · adjacent horizon·24 Jul · today
2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·23 Jul · today
Eternal shares may receive up to $650 million in inflows led by this positive trigger
NewsCnbc-Tv18·22 Jul · 2d ago
Biocon's Malaysia facility gets European regulator approval for new drug product fill finish for insulin
NewsCnbc-Tv18·16 Jul · 1w ago
Kiran Mazumdar-Shaw says Biocon succession is in place, bets on India's biopharma boom
NewsCnbc-Tv18·15 Jul · 1w ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.